Art Taveras

Dr. Art Taveras was previously employed as a Chief Scientific Officer by X4 Pharmaceuticals, Inc., a Chief Scientific Officer by Comet Therapeutics, Inc., a Chief Scientific Officer & Head-Drug Discovery by Transform Therapeutics, a President & Chief Scientific Officer by Shanghai ChemPartner Co., Ltd., a Vice President-Small Molecule Drug Discovery by Biogen Idec, Inc. (North Carolina), and a Vice President-Drug Discovery & Development by Alantos Pharmaceuticals Holding, Inc. He received his undergraduate degree from Rensselaer Polytechnic Institute, a graduate degree from Rensselaer Polytechnic Institute and a doctorate degree from Rensselaer Polytechnic Institute.